S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
S&P 500   4,397.94 (-1.89%)
DOW   34,265.37 (-1.30%)
QQQ   351.69 (-2.77%)
AAPL   162.41 (-1.28%)
MSFT   296.03 (-1.85%)
FB   303.17 (-4.23%)
GOOGL   2,607.03 (-2.22%)
AMZN   2,852.86 (-5.95%)
TSLA   943.90 (-5.26%)
NVDA   233.74 (-3.21%)
BABA   123.23 (-5.95%)
NIO   27.35 (-6.11%)
AMD   118.81 (-2.53%)
CGC   7.29 (-3.57%)
MU   81.93 (-3.69%)
GE   96.30 (-1.98%)
T   26.61 (-1.52%)
F   20.65 (-4.62%)
DIS   137.38 (-6.94%)
AMC   17.97 (-0.55%)
PFE   52.79 (-2.33%)
ACB   4.46 (-6.11%)
BA   205.44 (-4.09%)
NYSE:EW

Edwards Lifesciences Stock Forecast, Price & News

$112.65
-2.91 (-2.52%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$112.23
$115.55
50-Day Range
$107.31
$130.68
52-Week Range
$78.44
$131.73
Volume
3.13 million shs
Average Volume
2.25 million shs
Market Capitalization
$70.33 billion
P/E Ratio
47.94
Dividend Yield
N/A
Beta
1.1
30 days | 90 days | 365 days | Advanced Chart
Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.


Edwards Lifesciences logo

About Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
14,900
Year Founded
1958

Sales & Book Value

Annual Sales
$4.39 billion
Cash Flow
$2.00 per share
Book Value
$7.34 per share

Profitability

Net Income
$823.40 million
Pretax Margin
33.01%

Debt

Price-To-Earnings

Miscellaneous

Free Float
615,906,000
Market Cap
$70.33 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/27/2021
Today
1/21/2022
Next Earnings (Confirmed)
1/26/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.58 out of 5 stars

Medical Sector

199th out of 1,418 stocks

Surgical Appliances & Supplies Industry

7th out of 28 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -












Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

Is Edwards Lifesciences a buy right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences
or view top-rated stocks.

How has Edwards Lifesciences' stock price been impacted by Coronavirus (COVID-19)?

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EW shares have increased by 71.2% and is now trading at $112.65.
View which stocks have been most impacted by COVID-19
.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, January 26th 2022.
View our earnings forecast for Edwards Lifesciences
.

How can I listen to Edwards Lifesciences' earnings call?

Edwards Lifesciences will be holding an earnings conference call on Wednesday, January 26th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) posted its earnings results on Wednesday, October, 27th. The medical research company reported $0.54 EPS for the quarter, topping the Zacks' consensus estimate of $0.53 by $0.01. The medical research company earned $1.31 billion during the quarter, compared to analysts' expectations of $1.32 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 28.13% and a net margin of 29.00%. The company's quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.51 earnings per share.
View Edwards Lifesciences' earnings history
.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY 2022 earnings guidance on Wednesday, December, 8th. The company provided EPS guidance of $2.500-$2.650 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.580. The company issued revenue guidance of $5.50 billion-$6 billion, compared to the consensus revenue estimate of $5.85 billion.

What price target have analysts set for EW?

19 equities research analysts have issued 1-year price objectives for Edwards Lifesciences' shares. Their forecasts range from $85.00 to $148.00. On average, they anticipate Edwards Lifesciences' share price to reach $126.06 in the next year. This suggests a possible upside of 11.9% from the stock's current price.
View analysts' price targets for Edwards Lifesciences
or view top-rated stocks among Wall Street analysts.

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:
  • Michael A. Mussallem, Chairman & Chief Executive Officer
  • Scott B. Ullem, Chief Financial Officer & Vice President
  • Todd J. Brinton, Chief Scientific Officer & VP-Advanced Technology
  • Catherine M. Szyman, Vice President & General Manager-Critical Care
  • Arnold A. Pinkston, Vice President & General Counsel

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), salesforce.com (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.15%), Huntington National Bank (0.13%), Royal London Asset Management Ltd. (0.11%), Chicago Capital LLC (0.07%), Baillie Gifford & Co. (0.07%) and Frontier Capital Management Co. LLC (0.05%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends for Edwards Lifesciences
.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Russell Investments Group Ltd., Frontier Capital Management Co. LLC, Royal London Asset Management Ltd., IBM Retirement Fund, Chicago Capital LLC, Endurance Wealth Management Inc., and AE Wealth Management LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, and Nicholas J Valeriani.
View insider buying and selling activity for Edwards Lifesciences
or view top insider-selling stocks.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was bought by a variety of institutional investors in the last quarter, including Huntington National Bank, State of Alaska Department of Revenue, Stratos Wealth Partners LTD., Baillie Gifford & Co., Wedbush Securities Inc., DNB Asset Management AS, Kestra Private Wealth Services LLC, and Sterling Manor Financial LLC.
View insider buying and selling activity for Edwards Lifesciences
or or view top insider-buying stocks.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $112.65.

How much money does Edwards Lifesciences make?

Edwards Lifesciences has a market capitalization of $70.33 billion and generates $4.39 billion in revenue each year. The medical research company earns $823.40 million in net income (profit) each year or $2.35 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

Edwards Lifesciences employs 14,900 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.

When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

Where are Edwards Lifesciences' headquarters?

Edwards Lifesciences is headquartered at ONE EDWARDS WAY, IRVINE CA, 92614.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at (949) 250-2500, via email at [email protected], or via fax at 949-250-2525.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.